Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/134773
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Mateos, Maria Victoria | - |
dc.contributor.author | Bringhen, Sara | - |
dc.contributor.author | Richardson, Paul G. | - |
dc.contributor.author | Lahuerta, Juan José | - |
dc.contributor.author | García-Sanz, Ramón | - |
dc.contributor.author | San Miguel, Jesús F. | - |
dc.contributor.author | Palumbo, Antonio | - |
dc.date.accessioned | 2016-07-14T08:25:33Z | - |
dc.date.available | 2016-07-14T08:25:33Z | - |
dc.date.issued | 2014 | - |
dc.identifier | doi: 10.3324/haematol.2013.099341 | - |
dc.identifier | e-issn: 1592-8721 | - |
dc.identifier | issn: 0390-6078 | - |
dc.identifier.citation | Haematologica 99(6): 1114-1122 (2014) | - |
dc.identifier.uri | http://hdl.handle.net/10261/134773 | - |
dc.description.abstract | Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week once-weekly cycles. In the GIMEMA MM-03-05 study, the bortezomib-melphalan-prednisone regimen was either per VISTA ('GIMEMA twice-weekly'), or comprised nine 5-week once-weekly cycles ('GIMEMA once-weekly'). In the GEM2005MAS65 study, the regimen comprised one 6-week twice-weekly cycle, plus five 5-week once-weekly cycles. We evaluated the cumulative bortezomib dose administered during bortezomib-melphalan-prednisone, as well as efficacy and tolerability, using patient-level study data. Over all bortezomib-melphalan-prednisone cycles (nine in VISTA/GIMEMA; six in GEM2005MAS65), the median cumulative bortezomib dose administered was 38.5, 42.1, 40.3, and 32.9 mg/m2 in VISTA, GIMEMA twice-weekly, GIMEMA once-weekly, and GEM2005MAS65, respectively, and the respective proportions of planned bortezomib dose actually delivered were 57.0%, 62.3%, 86.1%, and 90.4%. Response rates following bortezomib-melphalan-prednisone were 74-87% and appeared generally similar between studies. Three-year survival rates were 67.9-75.7% across studies. Grade 3/4 peripheral neuropathy rates were 13% in VISTA and 14% in GIMEMA twice-weekly, but were lower at 2% in GIMEMA once-weekly and 7% in GEM2005MAS65. Discontinuations and bortezomib dose reductions due to peripheral neuropathy were reduced in GIMEMA once-weekly versus VISTA and GIMEMA twice-weekly. Exclusive or predominant use of once-weekly bortezomib dosing in GIMEMA once-weekly and GEM2005MAS65 resulted in high efficacy, comparable with that demonstrated in VISTA, and similar cumulative bortezomib dose with reduced toxicity. Trials are registered with ClinicalTrials.gov: VISTA (Identifier:00111319), GIMEMA MM-03-05 (Identifier:01063179), and GEM2005MAS65 (Identifier:00443235). | - |
dc.publisher | Ferrata Storti Foundation | - |
dc.rights | closedAccess | - |
dc.title | Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy | - |
dc.type | artículo | - |
dc.identifier.doi | 10.3324/haematol.2013.099341 | - |
dc.date.updated | 2016-07-14T08:25:34Z | - |
dc.description.version | Peer Reviewed | - |
dc.language.rfc3066 | eng | - |
dc.relation.csic | Sí | - |
dc.identifier.pmid | 24763402 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 09-abr-2024
SCOPUSTM
Citations
44
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
40
checked on 29-feb-2024
Page view(s)
236
checked on 19-abr-2024
Download(s)
80
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.